Elucidation of factors contributing to the development of skin disorders in patients treated with bendamustine and establishment of preventive methods

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K16429
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Doshisha Women's College of Liberal Arts (2021); Osaka University of Pharmaceutical Sciences (2019-2020)
• Principal Investigator: Mayako Uchida 同志社女子大学, 薬学部, 教授 (70784304)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: ベンダムスチン / 皮膚障害 / 副作用

Outline of Final Research Achievements

Bendamustine plays an especially important role as a treatment for non-Hodgkin lymphoma (NHL). However, patients administered bendamustine may experience drug-associated skin toxicities that can profoundly impact their health-related quality of life. Moreover, worsening skin symptoms may lead to dose reduction or termination in the management of cancer chemotherapy. We investigated patient backgrounds and pretreatment characteristics of NHL patients treated with bendamustine. Multivariate stepwise logistic regression analysis with backward sel ection revealed that baseline non-prior chemotherapy (odds ratio, 15.72; 95％ confidence interval, 4.24～83.13, p<0.001) was a significant factor influencing the occurrence of skin toxicity. Our results demonstrated that non-prior chemotherapy was a significant risk factor for skin toxicities in patients with NHL receiving bendamustine.

Free Research Field

がん化学療法

Academic Significance and Societal Importance of the Research Achievements

本結果は、ベンダムスチン療法施行前の前化学療法歴がベンダムスチン療法を受けるNHL患者における皮膚障害の重要な予測因子であることを示した。ベンダムスチンは外来で施行されるレジメンのため、医療従事者が日々患者の皮膚状態を観察することは困難である。
このため、本研究結果は、皮膚障害の発現リスクを事前に層別化するうえで非常に重要な情報となり、安全ながん化学療法の施行に貢献するものと考えられる。